{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:35:37Z","timestamp":1768322137209,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10549-025-07701-x","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:22:13Z","timestamp":1744802533000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor\u2013positive breast cancer"],"prefix":"10.1007","volume":"212","author":[{"given":"Connie","family":"Lau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"LaBorde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilqees","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahad S.","family":"Alfartosy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Abughosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0585-5580","authenticated-orcid":false,"given":"Meghana V.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"12","key":"7701_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"issue":"20","key":"7701_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and Letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"issue":"10","key":"7701_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942\u2013950. https:\/\/doi.org\/10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"issue":"7","key":"7701_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904\u2013915. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4","journal-title":"Lancet Oncol"},{"issue":"5","key":"7701_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M et al (2022) Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial. Clin Cancer Res 28(5):851\u2013859. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3032","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7701_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon DJ, Neven P, Chia S et al (2021) Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 32(8):1015\u20131024. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.353","journal-title":"Ann Oncol"},{"issue":"1","key":"7701_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge GW, Toi M, Neven P et al (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol 6(1):116\u2013124. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782","journal-title":"JAMA Oncol"},{"issue":"20","key":"7701_CR8","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1810527","journal-title":"N Engl J Med"},{"issue":"1","key":"7701_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J et al (2023) Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5","journal-title":"Lancet Oncol"},{"issue":"12","key":"7701_CR10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z et al (2024) Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 390(12):1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2305488","journal-title":"N Engl J Med"},{"issue":"2","key":"7701_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529\u2013537. https:\/\/doi.org\/10.1007\/s10549-010-1132-4","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7701_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-013-2422-4","volume":"138","author":"L Huiart","year":"2013","unstructured":"Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138(1):325\u2013328. https:\/\/doi.org\/10.1007\/s10549-013-2422-4","journal-title":"Breast Cancer Res Treat"},{"key":"7701_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","volume":"62","author":"I Yussof","year":"2022","unstructured":"Yussof I, Mohd Tahir NA, Hatah E, Mohamed SN (2022) Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review. Breast 62:22\u201335. https:\/\/doi.org\/10.1016\/j.breast.2022.01.012","journal-title":"Breast"},{"issue":"2","key":"7701_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459\u2013478. https:\/\/doi.org\/10.1007\/s10549-012-2114-5","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"7701_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.clbc.2020.06.004","volume":"20","author":"GS Hwang","year":"2020","unstructured":"Hwang GS, Paranjpe R, Opsomer C et al (2020) Oral endocrine therapy agent, race\/ethnicity, and time on therapy predict adherence in breast cancer patients in a large academic institution. Clin Breast Cancer 20(6):520\u2013526. https:\/\/doi.org\/10.1016\/j.clbc.2020.06.004","journal-title":"Clin Breast Cancer"},{"key":"7701_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12601","author":"J Brett","year":"2018","unstructured":"Brett J, Fenlon D, Boulton M et al (2018) Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care (Engl). https:\/\/doi.org\/10.1111\/ecc.12601","journal-title":"Eur J Cancer Care (Engl)."},{"key":"7701_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.conctc.2018.10.001","volume":"12","author":"P Chalela","year":"2018","unstructured":"Chalela P, Munoz E, Inupakutika D et al (2018) Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. Contemp Clin Trials Commun 12:109\u2013115. https:\/\/doi.org\/10.1016\/j.conctc.2018.10.001","journal-title":"Contemp Clin Trials Commun"},{"issue":"6","key":"7701_CR18","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s11096-023-01609-6","volume":"45","author":"S Rahimi","year":"2023","unstructured":"Rahimi S, Ononogbu O, Mohan A, Moussa D, Abughosh S, Trivedi MV (2023) Adherence to oral endocrine therapy in racial\/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic. Int J Clin Pharm 45(6):1396\u20131404. https:\/\/doi.org\/10.1007\/s11096-023-01609-6","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"7701_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clbc.2022.10.006","volume":"23","author":"S Martin","year":"2023","unstructured":"Martin S, Pflumio C, Trensz P et al (2023) Consequences of discontinuing a 4\/6 cyclin D-dependent kinase inhibitor during endocrine treatment in hormone-sensitive metastatic breast cancer patients in the context of the COVID-19 outbreak. Clin Breast Cancer 23(1):32\u201337. https:\/\/doi.org\/10.1016\/j.clbc.2022.10.006","journal-title":"Clin Breast Cancer"},{"issue":"21","key":"7701_CR20","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/ajhp\/zxac212","volume":"79","author":"AD Zuckerman","year":"2022","unstructured":"Zuckerman AD, Whelchel K, Kozlicki M et al (2022) Health-system specialty pharmacy role and outcomes: A review of current literature. Am J Health Syst Pharm 79(21):1906\u20131918. https:\/\/doi.org\/10.1093\/ajhp\/zxac212","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"7701_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.15386\/mpr-1201","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel LA, Farcas AM, Oprean RN (2019) An overview of the common methods used to measure treatment adherence. Med Pharm Rep 92(2):117\u2013122. https:\/\/doi.org\/10.15386\/mpr-1201","journal-title":"Med Pharm Rep"},{"issue":"2","key":"7701_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2018.08.006","volume":"22","author":"PP Pednekar","year":"2019","unstructured":"Pednekar PP, \u00c1gh T, Malmen\u00e4s M et al (2019) Methods for measuring multiple medication adherence: A systematic review-report of the ISPOR medication adherence and persistence special interest group. Value Health 22(2):139\u2013156. https:\/\/doi.org\/10.1016\/j.jval.2018.08.006","journal-title":"Value Health"},{"key":"7701_CR23","doi-asserted-by":"publisher","first-page":"1345482","DOI":"10.3389\/fphar.2024.1345482","volume":"15","author":"A Turcu-Stiolica","year":"2024","unstructured":"Turcu-Stiolica A, Udristoiu I, Subtirelu MS et al (2024) Digging in real-word electronic database for assessing CDK 4\/6 inhibitors adherence in breast cancer patients from Romania. Front Pharmacol 15:1345482. https:\/\/doi.org\/10.3389\/fphar.2024.1345482","journal-title":"Front Pharmacol"},{"issue":"5","key":"7701_CR24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1177\/10781552221102884","volume":"29","author":"A Marineau","year":"2023","unstructured":"Marineau A, St-Pierre C, Lessard-Hurtubise R, David M, Adam JP, Chabot I (2023) Cyclin-dependent kinase 4\/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO\/NCODA patient-centered standards in a community pharmacy. J Oncol Pharm Pract 29(5):1144\u20131153. https:\/\/doi.org\/10.1177\/10781552221102884","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"7701_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cncr.34675","volume":"129","author":"RK Goyal","year":"2023","unstructured":"Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML (2023) Overall survival associated with CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer 129(7):1051\u20131063. https:\/\/doi.org\/10.1002\/cncr.34675","journal-title":"Cancer"},{"key":"7701_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2147\/PPA.S401480","volume":"17","author":"NM Engel-Nitz","year":"2023","unstructured":"Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X (2023) Palbociclib adherence and persistence in patients with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2-) metastatic breast cancer. Patient Prefer Adherence 17:1049\u20131062. https:\/\/doi.org\/10.2147\/PPA.S401480","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"7701_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12913-017-2373-2","volume":"17","author":"M Stokes","year":"2017","unstructured":"Stokes M, Reyes C, Xia Y, Alas V, Goertz HP, Boulanger L (2017) Impact of pharmacy channel on adherence to oral oncolytics. BMC Health Serv Res 17(1):414. https:\/\/doi.org\/10.1186\/s12913-017-2373-2","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"7701_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.18553\/jmcp.2021.27.10.1438","volume":"27","author":"EC Academia","year":"2021","unstructured":"Academia EC, Mej\u00edas-De Jes\u00fas CM, Stevens JS et al (2021) Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies. J Manag Care Spec Pharm 27(10):1438\u20131446. https:\/\/doi.org\/10.18553\/jmcp.2021.27.10.1438","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"7701_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2478\/acph-2023-0045","volume":"73","author":"M Bakovi\u0107","year":"2023","unstructured":"Bakovi\u0107 M, Bago M, Beni\u0107 L et al (2023) Exploring adherence in patients with advanced breast cancer: focus on CDK4\/6 inhibitors. Acta Pharm 73(4):633\u2013654. https:\/\/doi.org\/10.2478\/acph-2023-0045","journal-title":"Acta Pharm"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07701-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T07:24:05Z","timestamp":1747553045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07701-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7701"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07701-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.N.B. has been awarded a Pfizer grant unrelated to the current project and has attended Pfizer US Medical Affairs Breast Cancer Advisory Board Meeting at the Hematology\/Oncology Pharmacy Association Annual 2023 Meeting. R.D.L.T. has been awarded a Pfizer grant unrelated to the current project. All other authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki and approved by the institutional review boards of the University of Houston and the Houston Methodist Hospital System (HM). Informed consent was waived for this retrospective analysis of the chart reviews.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}